98%
921
2 minutes
20
Transmembrane protein 40 (TMEM40) is a 23-kDa protein in cell membrane. There is no report that TMEM40 is associated with cancer. However, our study found that TMEM40 was high expressed in bladder cancer tissues. Immunohistochemical analyses of TMEM40 expression were performed on a tissue microarray including 72 transitional cell carcinomas and 43 normal bladder tissues to investigate the expression and clinical significance of TMEM40 in bladder cancer. We adopted receiver operating characteristic (ROC) analysis to select the optimal cut-off score. TMEM40 expression was defined positive if above 62.5% of cells were stained, and below it was negative. Then, the expression of TMEM40 in bladder cancer cells was evaluated by quantitative real-time PCR and western blot analysis. A significantly high level of TMEM40 in bladder cancer cells was proved. On the basis of ROC curve analysis, TMEM40 expression was positive in 68.1% (n=49) and negative in 31.9% (n=23) of bladder cancer cases. TMEM40 staining was positive in 2.3% (n=1) and negative in 97.7% (n=42) of normal bladder tissues. It showed that TMEM40 was up-regulated in bladder cancer tissues compared to normal bladder tissues. Moreover, TMEM40 expression was significantly associated with histological grade (<0.05), clinical stage (<0.05), pT status (<0.05), but not age. Our study demonstrates that high TMEM40 expression is associated with bladder cancer, and it could be a diagnostic biomarker for bladder cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965264 | PMC |
Biomed Rep
November 2025
College of Public Health, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
flavones (PRFs), bioactive components derived from the plant, exhibit anti-inflammatory and anti-tumor properties. However, their therapeutic potential for bladder cancer remains poorly understood. The present study aimed to investigate the anti-tumor effects and molecular mechanisms underlying the effects of PRF on human bladder cancer T24 cells.
View Article and Find Full Text PDFAdv Radiat Oncol
October 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology and Radiotherapy, Augustenburger Platz 1, 13353 Berlin, Germany.
Purpose: To evaluate the impact of an optimized online adaptive radiation therapy workflow on physician involvement.
Methods And Materials: Data from a prospective phase 2 trial involving 34 prostate cancer patients treated with cone beam computed tomography (CBCT)-based online adaptive radiation therapy (62 Gy in 20 fractions) were analyzed. Manual interventions were required for 2 steps in the workflow: radiation therapy technologist review and adjustment of automatically segmented organs, guiding target segmentation, so-called "influencer," while physicians reviewed and refined the targets.
Ther Adv Urol
September 2025
Department of Urology, Peking University People's Hospital, 11 Xizhimen South Street, Haidian District, Beijing 100044, China.
Objective: Many studies have stressed the necessity of repeat transurethral resection (reTURB) following the initial conventional transurethral resection of the bladder for non-muscle invasive bladder cancer (NMIBC) patients. However, there have been few studies focusing on the role of reTURB after en bloc resection of bladder tumor (ERBT) for NMIBC by far. This study aimed to evaluate whether reTURB can be avoided after ERBT.
View Article and Find Full Text PDFJ Appl Clin Med Phys
September 2025
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Purpose: This study aims to assess percentage of automated AIO plans that met clinical treatment standards of radiotherapy plans generated by the fully automated All-in-one (AIO) process.
Methods: The study involved 117 rectal cancer patients who underwent AIO treatment. Fully automated regions of interest (ROI) and treatment plans were developed without manual intervention, comparing them to manually generated plans used in clinical practice.
Curr Med Imaging
May 2025
Department of Radiology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Background: Predicting the recurrence risk of NMIBC after TURBT is crucial for individualized clinical treatment.
Objective: The objective of this study is to evaluate the ability of radiomic feature analysis of intratumoral and peritumoral regions based on computed tomography (CT) imaging to predict recurrence in non-muscle-invasive bladder cancer (NMIBC) patients who underwent transurethral resection of bladder tumor (TURBT).
Methods: A total of 233 patients with NMIBC who underwent TURBT were retrospectively analyzed.